• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study.

作者信息

Sprague Stuart M, Edelstein Susan, Spiegel David M, Rosenbaum David P, Thomas Cher, Weiner Daniel E

机构信息

Endeavor Health/NorthShore University HealthSystem, Evanston, IL, USA.

University of Chicago Pritzker School of Medicine, Chicago, IL, USA.

出版信息

Curr Med Res Opin. 2024 Aug;40(8):1335-1343. doi: 10.1080/03007995.2024.2364815. Epub 2024 Jul 23.

DOI:10.1080/03007995.2024.2364815
PMID:39041739
Abstract
摘要

相似文献

1
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study.替那帕诺治疗接受透析患者高磷血症的有效性：OPTIMIZE研究的通俗易懂总结
Curr Med Res Opin. 2024 Aug;40(8):1335-1343. doi: 10.1080/03007995.2024.2364815. Epub 2024 Jul 23.
2
Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study.替那帕诺可改善维持性透析患者长期的高血磷控制：NORMALIZE研究的通俗概述
Curr Med Res Opin. 2024 Aug;40(8):1345-1356. doi: 10.1080/03007995.2024.2364824. Epub 2024 Jul 23.
3
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).一项关于特立帕肽联合磷酸盐结合剂作为维持性透析患者高磷血症双联治疗的随机试验（AMPLIFY）
J Am Soc Nephrol. 2021 Jun 1;32(6):1465-1473. doi: 10.1681/ASN.2020101398. Epub 2021 Mar 25.
4
Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.添加用特立帕肽治疗血液透析伴难治性高磷血症患者的疗效。
Am J Nephrol. 2021;52(6):496-506. doi: 10.1159/000516156. Epub 2021 Jun 7.
5
Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia.替那帕诺：一种用于治疗透析高磷血症患者的新型治疗药物。
Ther Apher Dial. 2025 Apr;29(2):157-169. doi: 10.1111/1744-9987.14241. Epub 2025 Jan 19.
6
Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies.钠氢交换体3抑制剂替那帕诺作为慢性肾脏病高磷血症创新疗法的有效性和安全性概况：临床研究的系统评价
Nefrologia (Engl Ed). 2024 Nov-Dec;44(6):796-806. doi: 10.1016/j.nefroe.2024.11.015.
7
Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure.替那帕诺：一种用于治疗肾衰竭患者高磷血症的磷酸盐吸收抑制剂。
J Ren Nutr. 2025 Jan;35(1):25-34. doi: 10.1053/j.jrn.2024.07.003. Epub 2024 Jul 9.
8
Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients.替那帕诺与安慰剂治疗透析及高磷血症慢性肾脏病患者的疗效与安全性：对2251例患者的系统评价与荟萃分析
Int Urol Nephrol. 2025 Jun;57(6):1835-1850. doi: 10.1007/s11255-024-04316-x. Epub 2024 Dec 19.
9
Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.替那帕诺对接受血液透析患者血清磷酸盐的影响。
J Am Soc Nephrol. 2017 Jun;28(6):1933-1942. doi: 10.1681/ASN.2016080855. Epub 2017 Feb 3.
10
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.在接受维持性血液透析的高磷血症患者中，他纳诺尔的疗效和安全性：一项随机 3 期试验。
J Am Soc Nephrol. 2019 Apr;30(4):641-652. doi: 10.1681/ASN.2018080832. Epub 2019 Mar 7.